Edgar Filing: ISALY SAMUEL D

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â ORBIMED ADVISORS LLC

2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2010

3. Issuer Name and Ticker or Trading Symbol
Anthera Pharmaceuticals Inc [ANTH]

(Last)

(First)

(Middle)

767 3RD AVENUE,Â 30TH FLOOR

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

NEW YORK,Â NYÂ 10017

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,429,834	I	See Footnotes ⁽¹⁾ ⁽²⁾ ⁽⁴⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to Purchase Common Stock	09/24/2010	09/24/2015	Common Stock	1,333,334	$ 3.3	I	See Footnotes ⁽¹⁾ ⁽²⁾ ⁽³⁾ ⁽⁴⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
ORBIMED ADVISORS LLC 767 3RD AVENUE 30TH FLOOR NEW YORK,Â NYÂ 10017	Â	Â X	Â	Â
OrbiMed Capital GP IV LLC 767 THIRD AVENUE, 30TH FLOOR NEW YORK,Â NYÂ 10017	Â	Â X	Â	Â
ISALY SAMUEL D 767 THIRD AVENUE, 30TH FLOOR NEW YORK,Â NYÂ 10017	Â	Â X	Â	Â

Signatures

OrbiMed Advisors LLC, /s/ Samuel D. Isaly, Managing Member		10/04/2010
^**Signature of Reporting Person		Date
OrbiMed Capital GP IV LLC, By: OrbiMed Advisors LLC, /s/Samuel D. Isaly, Managing Member		10/04/2010
^**Signature of Reporting Person		Date
Samuel D. Isaly, /s/ Samuel D. Isaly		10/04/2010
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The shares of Common Stock ("Shares") reported herein as indirectly beneficially owned by OrbiMed Capital GP IV LLC ("OrbiMed Capital"), OrbiMed Advisors LLC ("OrbiMed Advisors") and Samuel D. Isaly ("Isaly") are directly owned by Caduceus Private Investments IV, LP ("Caduceus) and each of OrbiMed Capital, OrbiMed Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by Caduceus. This Form 3 is being jointly filed by OrbiMed Capital, OrbiMed Advisors and Isaly.
(2)	OrbiMed Capital is the sole general partner of Caduceus. OrbiMed Advisors is a registered adviser under the Investment Advisers Act of 1940, as amended, and the sole managing member of OrbiMed Capital GP IV. OrbiMed Advisors and OrbiMed Capital may be deemed to have beneficial ownership of the Shares and the Warrant (as defined in Footnote 4 below) reported herein by virtue of such relationships and the authority of OrbiMed Capital to direct the vote and disposition of the Shares and the Warrant held by Caduceus. Isaly, a natural person, may be deemed to have beneficial ownership of the Shares and the Warrant reported herein in his capacity as the holder of a controlling interest in OrbiMed Advisors.
(3)	Caduceus holds a warrant to purchase 1,333,334 shares of Common Stock ("Warrant").
(4)	Each of OrbiMed Advisors, OrbiMed Capital GP IV and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.